BFRI Biofrontera Inc.
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.55
P/S
0.24
EV/EBITDA
-1.42
DCF Value
$-29.82
FCF Yield
-90.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
82.8%
Operating Margin
-20.6%
Net Margin
-25.7%
ROE
-476.7%
ROA
-44.7%
ROIC
-62.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $10.1M | $-4.8M | $— |
| Q4 null | $17.1M | $5.6M | $— |
| FY null | $41.7M | $-10.5M | $— |
| Q3 null | $7.0M | $-6.6M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US
Exchange
—
Beta
0.91
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.